What dose considerations should be taken when prescribing moxonidine for CKD patients?
Moxonidine is extensively excreted by the kidney and accordingly it has been recommended that the dosage (usually 200 to 400 mg daily) should be reduced in the presence of a low GFR. Additionally, common severe adverse events associated with moxonidine in clinical trials include gastrointestinal symptoms, dizziness, headache and tiredness, all of which occurred in between 10 to 15% of the patients receiving moxonidine. 